A rare complication of ulcerative colitis in children: Pyoderma gangrenosum

Yıl 2020, , 23 - 26, 31.03.2020

Ulaş Emre Akbulut , İshak Işık , Bilge Aldemir Kocabaş Fatih Ay Hülya Tosun Yıldırım

https://doi.org/10.33204/mucosa.699500

Öz

Pyoderma gangrenosum (PG) is a rare inflammatory skin disease mainly characterized by ulcers. More than half of the PG is associated with systemic diseases like inflammatory bowel disease. About 4% of PG is seen during childhood. Here we report a 12-year-old girl presented with fever and bloody diarrhea and who developed a painful leg ulcer during follow up period and diagnosed as ulcerative colitis.

Anahtar Kelimeler

Ulcerative colitis, Pyoderma gangrenosum, Children

Çocuklarda ülseratif kolitin nadir bir komplikasyonu: Piyoderma gangrenozum

Öz

Piyoderma gangrenozum (PG), esas olarak ülserlerle karakterize nadir görülen bir inflamatuar deri hastalığıdır. PG’nin yarısından fazlası, inflamatuar bağırsak hastalığı gibi sistemik hastalıklarla ilişkilidir. Olguların yaklaşık %4’ü çocukluk döneminde görülür. Burada ateş ve kanlı ishal ile başvuran, takip döneminde ağrılı bacak ülseri gelişen ve ülseratif kolit tanısı konulan 12 yaşında bir kız hastayı sunuyoruz.

Anahtar Kelimeler

ülseratif kolit, piyoderma gangrenozum, çocuklar

Kaynakça

• 1. Arguelles-Arias F, Castro-Laria L, Lobaton T, et al. Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease. Dig Dis Sci 2013;58:2949-54.
• 2. Soleimani T, Sasor SE, Spera L, et al. Pediatric pyoderma gangrenosum: is it just big wounds on little adults? J Surg Res 2016;206:113-7.
• 3. Kechichian E, Haber R, Mourad N, et al. Pediatric pyoderma gangrenosum: a systematic review and update. Int J Dermatol 2017;56:486-95.
• 4. Bissonnette C, Kauzman A, Mainville GN. Oral pyoderma gangrenosum: diagnosis, treatment and challenges: a systematic review. Head Neck Pathol 2017;11:427-41.
• 5. Niu R, Zheng J, Ding D, et al. Giant pyoderma gangrenosum in a patient with ulcerative colitis: A case report. Medicine (Baltimore) 2020;99:e18795.
• 6. Zampeli VA, Lippert U, Nikolakis G, et al. Disseminated refractory pyoderma gangraenosum during an ulcerative colitis flare.Treatment with infliximab. J Dermatol Case Rep 2015;9:62-6.
• 7. Brooklyn T, Dunnill MG, Probert C. Diagnosis and treatment of pyoderma gangrenosum. BMJ 2006;22:181-4.
• 8. Miller J, Yentzer BA, Clark A, et al. Pyoderma gangrenosum: a review and update on new therapies. J Am Acad Dermatol 2010;62:646-54.
• 9. Wollina U. Pyoderma gangrenosum: a review. Orphanet J Rare Dis 2007;15:1-8.
• 10. Futami H, Kodaira M, Furuta T, et al. Pyoderma gangrenosum complicating ulcerative colitis: Successful treatment with methylprednisolone pulse therapy and cyclosporine. J Gastroenterol 1998;33:408-11.
• 11. Powell RJ, Holbrook MR, Stevens A. Pyoderma gangrenosum and its treatment. Lancet 1997;350:1720-1.
• 12. Gettler S, Rothe M, Grin C, et al. Optimal treatment of pyoderma gangrenosum. Am J Clin Dermatol 2003;4:597-608.
• 13. Regueiro M, Valentine J, Plevy S, et al. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol 2003;98:1821-6.
• 14. Kim TY, Han DS, Eun CS, et al. Recombinant human epidermal growth factor enhances wound healing of pyoderma gangrenosum in a patient with ulcerative colitis. Inflamm Bowel Dis 2008;14:725-7.
• 15. Charles CA, Leon A, Banta MR, et al. Etanercept for the treatment of refractory pyoderma gangrenosum: a brief series. Int J Dermatol 2007;46:1095-9.
• 16. Fahmy M, Ramamoorthy S, Hata T, et al. Ustekinumab for peristomal pyoderma gangrenosum. Am J Gastroenterol 2012;107:794-5.
• 17. Brenner M, Ruzicka T, Plewig G, et al. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol 2009;161:1199-201.
• 18. Geusau A, Mothes-Luksch N, Nahavandi H et al. Identification of a homozygous PSTPIP1 mutation in a patient with a PAPA-like syndrome responding to canakinumab treatment. JAMA Dermatol 2013;149:209-15.